BRAF and AL amyloidosis: Moreover, t(14;16) with a mutation in B-Raf proto-oncogene(BRAF) exits in a small subset of patients with newly diagnosed multiple myeloma, this mutation has been observed to be associated with an increased incidence of advanced refractory disease and unfavorable outcomes (35).